Gilead Sciences Stock News

Regeneron Pharmaceuticals stock increased by 19% over the past month driven by strong third-quarter earnings and robust sales of its flagship drugs, Dupixent (for eczema and other inflammatory conditions) and Libtayo (for cancer).

FOSTER CITY, Calif.--(BUSINESS WIRE)--Gilead Sciences, Inc. (NASDAQ: GILD) today announced positive topline results from the Phase 3 ARTISTRY-1 trial. The open-label trial evaluated the treatment responses of adults with HIV who are virologically suppressed switching from a multi-tablet regimen to an investigational single-tablet regimen of bictegravir 75 mg/lenacapavir 50 mg (BIC/LEN). BIC/LEN...

Gilead Sciences, Inc. ( GILD ) UBS Global Healthcare Conference 2025 November 10, 2025 11:00 AM EST Company Participants Andrew Dickinson - Chief Financial Officer Presentation Unknown Analyst Good morning, everyone. My name is [ Dina Elmonshed.

LOS ANGELES--(BUSINESS WIRE)--As the pharmaceutical industry gathers for the Global Pharma & Biotech Summit in London this week, AIDS Healthcare Foundation (AHF) is launching a mobile billboard that will circle the venue (Convene 22 Bishopsgate) on Nov. 11-12 to spotlight Gilead Sciences' greed and refusal to make its breakthrough HIV prevention drug lenacapavir truly affordable and accessible....

Gilead Sciences said on Friday its breast cancer drug Trodelvy failed to meet the main goal of a late-stage study.

FOSTER CITY, Calif.--(BUSINESS WIRE)--Gilead Sciences, Inc. (Nasdaq: GILD) today announced the Phase 3 ASCENT-07 study investigating Trodelvy® (sacituzumab govitecan-hziy) versus chemotherapy as a first-line treatment post-endocrine therapy in HR+/HER2-negative metastatic breast cancer patients did not meet the primary endpoint of progression-free survival (PFS) as assessed by Blinded Independe...

FOSTER CITY, Calif.--(BUSINESS WIRE)--Gilead Sciences, Inc. (Nasdaq: GILD) today announced new long-term data reinforcing the safety and efficacy profile of Livdelzi® (seladelpar) for people living with primary biliary cholangitis (PBC). Findings support Livdelzi's consistent efficacy and safety outcomes in patients switching from obeticholic acid and positive impact on liver stiffness over 3 y...

When it comes to long-term growth in the stock market, cash is king. In this article, we're specifically looking at free cash flow (FCF).